1. Disease Information
Overview
Transaldolase deficiency is a rare autosomal recessive metabolic disorder characterized by impaired function of the transaldolase enzyme. This enzyme plays a critical role in the pentose phosphate pathway, influencing cellular redox balance and nucleotide synthesis.
Key Identifiers
- OMIM: 606003
- Orphanet: 1930
- ICD-10: E88.8 (Other specified metabolic disorders)
- MeSH: D055443
- Mondo ID: MONDO:0010173
Synonyms
- TALDO Deficiency
- Taldo Deficiency
Data Source
The information derives from aggregated disease-level resources, primarily based on case reports and small patient cohorts due to its rarity.
2. Etiology
Disease Causal Factors
Genetic: Caused by mutations in the TALDO1 gene, which disrupt the function of the transaldolase enzyme (PMID: 15489859).
Risk Factors
Genetic: Mutations like c.708G>A, c.272_273del (PMID: 15489859).
Protective Factors
There are no well-documented genetic or environmental protective factors due to the rarity of the condition.
Gene-Environment Interactions
No significant gene-environment interactions have been documented.
3. Phenotypes
Phenotype Type
- Symptoms: Hepatomegaly, liver failure, metabolic acidosis, and congenital heart defects (PMID: 15489859).
Phenotype Characteristics
- Age of Onset: Early infancy
- Symptom Severity: Severe; can be life-threatening
- Progression: Progressive liver and multiorgan failure
- Frequency: Present in all documented cases but based on a small sample size
Quality of Life Impact
Significant impact due to severe hepatomegaly and progressive liver failure. Affected individuals require comprehensive medical care.
Suggested HPO Terms
- Hepatomegaly (HP:0002240)
- Liver failure (HP:0001395)
4. Genetic/Molecular Information
Causal Genes
- Gene: TALDO1
- OMIM ID: 602061
Pathogenic Variants
- Variant Type: Missense, nonsense
- Allele Frequency: Rare in general population databases
- Somatic vs. Germline Origin: Germline mutations
Functional Consequences
Loss of function leading to disruption of metabolic flux in the pentose phosphate pathway.
5. Environmental Information
Environmental Factors
No specific environmental factors have been implicated due to the genetic nature of the disorder.
Lifestyle Factors
No documented influence of lifestyle on the disorder's presentation or severity.
6. Mechanism / Pathophysiology
Molecular Pathways
Involves the pentose phosphate pathway; impairment leads to reduced antioxidant capacity and accumulation of toxic sugar metabolites (PMID: 15489859).
Protein Dysfunction
Enzyme deficiency results in abnormal cellular redox states and impaired nucleotide synthesis, leading to cell damage.
Metabolic Changes
Increased glutaric acid levels, reduced ribose-5-phosphate, and erythrose-4-phosphate.
7. Anatomical Structures Affected
Organ Level
- Primary: Liver
- Secondary: Heart
Tissue and Cell Level
- Tissue Type: Hepatic tissue
- Cell Populations: Hepatocytes
Subcellular Level
- Cellular Compartments: Cytoplasm, where the enzyme primarily functions.
Localization
- Anatomical Sites: Liver, potential involvement of cardiac tissue (UBERON:0002107).
8. Temporal Development
Onset
- Age of Onset: Congenital to early infancy
- Onset Pattern: Chronic, insidious
Progression
- Rate: Rapid if untreated, with progressive liver failure
Patterns
Consistent progressive degeneration without remission
9. Inheritance and Population
Epidemiology
- Prevalence: Extremely rare; exact prevalence not well-documented.
- Inheritance Pattern: Autosomal recessive
Population Demographics
- No specific ethnic or demographic predilection identified.
10. Diagnostics
Clinical Tests
- Laboratory Tests: Measurement of pentose phosphate pathway metabolites
- Genetic Testing: Mutation analysis of TALDO1 via sequencing or specific gene panels
Genetic Testing
- Whole Exome Sequencing (WES): Preferred for diagnosing unknown metabolic disorders
Clinical Criteria
Diagnosis based on clinical presentation, biochemical testing, and genetic confirmation.
11. Outcome/Prognosis
Survival and Mortality
- Mortality Rate: High without treatment due to liver failure
Morbidity and Function
Significant disability due to liver dysfunction.
12. Treatment
Pharmacotherapy
- Supportive Care: Managing liver symptoms, addressing metabolic crises
- Liver Transplant: Considered in severe cases for liver failure (MAXO:0001198).
13. Prevention
Genetic Counseling
- Essential for families with known mutations, especially for planning future pregnancies.
14. Other Species / Natural Disease
No comparative animal models identified; condition largely unique to humans.
15. Model Organisms
No specific model organisms are used due to the rare nature of the disease and availability of clinical data.
This report integrates current knowledge on Transaldolase Deficiency relevant to clinical, genetic, and biochemical domains. Further research is critical to expand therapeutic and diagnostic developments. For comprehensive primary sources, please access linked PubMed articles using provided PMIDs.